Intravenously Infused Stem Cells for Cancer Treatment

Despite the recent influx of immunotherapies and small molecule drugs to treat tumors, cancer remains a leading cause of death in the United States, in large part due to the difficulties of treating metastatic cancer. Stem cells, which are inherently tumoritropic, provide a useful drug delivery vehi...

Full description

Saved in:
Bibliographic Details
Published in:Stem cell reviews and reports 2021-12, Vol.17 (6), p.2025-2041
Main Authors: Mercer-Smith, Alison R., Findlay, Ingrid A., Bomba, Hunter N., Hingtgen, Shawn D.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Cell Biology
Life Sciences
Regenerative Medicine/Tissue Engineering
Stem Cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83
cites cdi_FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83
container_end_page 2041
container_issue 6
container_start_page 2025
container_title Stem cell reviews and reports
container_volume 17
creator Mercer-Smith, Alison R.
Findlay, Ingrid A.
Bomba, Hunter N.
Hingtgen, Shawn D.
description Despite the recent influx of immunotherapies and small molecule drugs to treat tumors, cancer remains a leading cause of death in the United States, in large part due to the difficulties of treating metastatic cancer. Stem cells, which are inherently tumoritropic, provide a useful drug delivery vehicle to target both primary and metastatic tumors. Intravenous infusions of stem cells carrying or secreting therapeutic payloads show significant promise in the treatment of cancer. Stem cells may be engineered to secrete cytotoxic products, loaded with oncolytic viruses or nanoparticles containing small molecule drugs, or conjugated with immunotherapies. Herein we describe these preclinical and clinical studies, discuss the distribution and migration of stem cells following intravenous infusion, and examine both the limitations of and the methods to improve the migration and therapeutic efficacy of tumoritropic, therapeutic stem cells. Graphical abstract
doi_str_mv 10.1007/s12015-021-10192-0
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2542359529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0Eoqj0D3BAOXIJ-JnEFyQU8ahUiQPlbDnJuqRKnGInlfrvcUmp4MLJK-3MePZD6IrgW4JxeucJxUTEmJKYYCJpjE_QBU2ojBlN09PjnMgJmnm_xhhThnnwnKMJ44RlnJILJOa2d3oLtht8s4vm1gwequithzbKoWl8ZDoX5dqW4KKlA923YPtLdGZ042F2eKfo_elxmb_Ei9fnef6wiEvOkz5OsjQtjKl0xlhpMgGhQkZLKishgRAjykQImhDNs8pwXklgBQctCqMxrqqMTdH9mLsZihaqEvZlG7VxdavdTnW6Vn83tv5Qq26rsgTTlPAQcHMIcN3nAL5Xbe3LcJe2EC5WVHDKhBRUBikdpaXrvHdgjt8QrPbI1YhcBeTqG7nCwXT9u-DR8gM4CNgo8GFlV-DUuhucDdD-i_0CHceMWQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2542359529</pqid></control><display><type>article</type><title>Intravenously Infused Stem Cells for Cancer Treatment</title><source>Springer Nature</source><creator>Mercer-Smith, Alison R. ; Findlay, Ingrid A. ; Bomba, Hunter N. ; Hingtgen, Shawn D.</creator><creatorcontrib>Mercer-Smith, Alison R. ; Findlay, Ingrid A. ; Bomba, Hunter N. ; Hingtgen, Shawn D.</creatorcontrib><description>Despite the recent influx of immunotherapies and small molecule drugs to treat tumors, cancer remains a leading cause of death in the United States, in large part due to the difficulties of treating metastatic cancer. Stem cells, which are inherently tumoritropic, provide a useful drug delivery vehicle to target both primary and metastatic tumors. Intravenous infusions of stem cells carrying or secreting therapeutic payloads show significant promise in the treatment of cancer. Stem cells may be engineered to secrete cytotoxic products, loaded with oncolytic viruses or nanoparticles containing small molecule drugs, or conjugated with immunotherapies. Herein we describe these preclinical and clinical studies, discuss the distribution and migration of stem cells following intravenous infusion, and examine both the limitations of and the methods to improve the migration and therapeutic efficacy of tumoritropic, therapeutic stem cells. Graphical abstract</description><identifier>ISSN: 2629-3269</identifier><identifier>EISSN: 2629-3277</identifier><identifier>DOI: 10.1007/s12015-021-10192-0</identifier><identifier>PMID: 34138421</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Cell Biology ; Life Sciences ; Regenerative Medicine/Tissue Engineering ; Stem Cells</subject><ispartof>Stem cell reviews and reports, 2021-12, Vol.17 (6), p.2025-2041</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83</citedby><cites>FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83</cites><orcidid>0000-0003-4355-2377</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34138421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mercer-Smith, Alison R.</creatorcontrib><creatorcontrib>Findlay, Ingrid A.</creatorcontrib><creatorcontrib>Bomba, Hunter N.</creatorcontrib><creatorcontrib>Hingtgen, Shawn D.</creatorcontrib><title>Intravenously Infused Stem Cells for Cancer Treatment</title><title>Stem cell reviews and reports</title><addtitle>Stem Cell Rev and Rep</addtitle><addtitle>Stem Cell Rev Rep</addtitle><description>Despite the recent influx of immunotherapies and small molecule drugs to treat tumors, cancer remains a leading cause of death in the United States, in large part due to the difficulties of treating metastatic cancer. Stem cells, which are inherently tumoritropic, provide a useful drug delivery vehicle to target both primary and metastatic tumors. Intravenous infusions of stem cells carrying or secreting therapeutic payloads show significant promise in the treatment of cancer. Stem cells may be engineered to secrete cytotoxic products, loaded with oncolytic viruses or nanoparticles containing small molecule drugs, or conjugated with immunotherapies. Herein we describe these preclinical and clinical studies, discuss the distribution and migration of stem cells following intravenous infusion, and examine both the limitations of and the methods to improve the migration and therapeutic efficacy of tumoritropic, therapeutic stem cells. Graphical abstract</description><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Cell Biology</subject><subject>Life Sciences</subject><subject>Regenerative Medicine/Tissue Engineering</subject><subject>Stem Cells</subject><issn>2629-3269</issn><issn>2629-3277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEtPwzAQhC0Eoqj0D3BAOXIJ-JnEFyQU8ahUiQPlbDnJuqRKnGInlfrvcUmp4MLJK-3MePZD6IrgW4JxeucJxUTEmJKYYCJpjE_QBU2ojBlN09PjnMgJmnm_xhhThnnwnKMJ44RlnJILJOa2d3oLtht8s4vm1gwequithzbKoWl8ZDoX5dqW4KKlA923YPtLdGZ042F2eKfo_elxmb_Ei9fnef6wiEvOkz5OsjQtjKl0xlhpMgGhQkZLKishgRAjykQImhDNs8pwXklgBQctCqMxrqqMTdH9mLsZihaqEvZlG7VxdavdTnW6Vn83tv5Qq26rsgTTlPAQcHMIcN3nAL5Xbe3LcJe2EC5WVHDKhBRUBikdpaXrvHdgjt8QrPbI1YhcBeTqG7nCwXT9u-DR8gM4CNgo8GFlV-DUuhucDdD-i_0CHceMWQ</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Mercer-Smith, Alison R.</creator><creator>Findlay, Ingrid A.</creator><creator>Bomba, Hunter N.</creator><creator>Hingtgen, Shawn D.</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4355-2377</orcidid></search><sort><creationdate>20211201</creationdate><title>Intravenously Infused Stem Cells for Cancer Treatment</title><author>Mercer-Smith, Alison R. ; Findlay, Ingrid A. ; Bomba, Hunter N. ; Hingtgen, Shawn D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Cell Biology</topic><topic>Life Sciences</topic><topic>Regenerative Medicine/Tissue Engineering</topic><topic>Stem Cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mercer-Smith, Alison R.</creatorcontrib><creatorcontrib>Findlay, Ingrid A.</creatorcontrib><creatorcontrib>Bomba, Hunter N.</creatorcontrib><creatorcontrib>Hingtgen, Shawn D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Stem cell reviews and reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mercer-Smith, Alison R.</au><au>Findlay, Ingrid A.</au><au>Bomba, Hunter N.</au><au>Hingtgen, Shawn D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenously Infused Stem Cells for Cancer Treatment</atitle><jtitle>Stem cell reviews and reports</jtitle><stitle>Stem Cell Rev and Rep</stitle><addtitle>Stem Cell Rev Rep</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>17</volume><issue>6</issue><spage>2025</spage><epage>2041</epage><pages>2025-2041</pages><issn>2629-3269</issn><eissn>2629-3277</eissn><abstract>Despite the recent influx of immunotherapies and small molecule drugs to treat tumors, cancer remains a leading cause of death in the United States, in large part due to the difficulties of treating metastatic cancer. Stem cells, which are inherently tumoritropic, provide a useful drug delivery vehicle to target both primary and metastatic tumors. Intravenous infusions of stem cells carrying or secreting therapeutic payloads show significant promise in the treatment of cancer. Stem cells may be engineered to secrete cytotoxic products, loaded with oncolytic viruses or nanoparticles containing small molecule drugs, or conjugated with immunotherapies. Herein we describe these preclinical and clinical studies, discuss the distribution and migration of stem cells following intravenous infusion, and examine both the limitations of and the methods to improve the migration and therapeutic efficacy of tumoritropic, therapeutic stem cells. Graphical abstract</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34138421</pmid><doi>10.1007/s12015-021-10192-0</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-4355-2377</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2629-3269
ispartof Stem cell reviews and reports, 2021-12, Vol.17 (6), p.2025-2041
issn 2629-3269
2629-3277
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602714
source Springer Nature
subjects Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Cell Biology
Life Sciences
Regenerative Medicine/Tissue Engineering
Stem Cells
title Intravenously Infused Stem Cells for Cancer Treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A33%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenously%20Infused%20Stem%20Cells%20for%20Cancer%20Treatment&rft.jtitle=Stem%20cell%20reviews%20and%20reports&rft.au=Mercer-Smith,%20Alison%20R.&rft.date=2021-12-01&rft.volume=17&rft.issue=6&rft.spage=2025&rft.epage=2041&rft.pages=2025-2041&rft.issn=2629-3269&rft.eissn=2629-3277&rft_id=info:doi/10.1007/s12015-021-10192-0&rft_dat=%3Cproquest_pubme%3E2542359529%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-6877bffda833cf85e02382c29d59e11f5c655261a48df44d9e3b4ea5bfa00dd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2542359529&rft_id=info:pmid/34138421&rfr_iscdi=true